Director for Mayo Clinic’s Center for Regenerative Medicine
Dr. Allickson has a doctorate in health sciences along with a master’s in medical laboratory sciences. An experienced scientist with regulatory expertise, she has more than 25 years of experience in clinical translation of cellular therapies and regenerative medicine products including business management and board directorship experience.
At the Institute, Dr. Allickson heads the clinical translation team streamlining development to create a robust pipeline of products in early phase clinical trials and FDA registered products including cell therapy, tissue engineered organs and tissues, biomaterials and devices. She is one of the founding members of the International Society of Cellular Therapy and has been a member of the American Association of Blood Banks (AABB) for 29 years. Dr. Allickson is on the Board of Directors for AABB and IWEUS Capital along with Regenerative Medicine Outcomes Foundation as a scientific advisor, editorial board of CELLR4, vice chair for Cord Blood Association Quality Committee, Technical Advisory Board for Tissue Engineered Products under ICCBBA, grant reviewer for state funded initiatives such as CIRM and serves on the ISCT Commercialization Committee.